Novara Mark David
Known title: EVP & CHIEF COMMERCIAL OFFICERCIK: 0002000342
Novara Mark David's purchase track record
Novara Mark David has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/15/2024 | TNDM | $12K | +22.4% | -15.6% | +1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TNDM | ▲ Buy | Option Exercise | 76 | $0 | 5/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 57 | $731 | 5/15/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 10,496 | $0 | 5/15/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 7,854 | $101K | 5/15/2026 | View on chart |
| TNDM | ▼ Sell | Open Market | 187 | $4K | 3/17/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 5,540 | $120K | 3/16/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 7,414 | $0 | 3/16/2026 | View on chart |
| TNDM | ▼ Sell | Open Market | 2 | $46 | 3/5/2026 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 77 | $0 | 2/17/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 62 | $1K | 2/17/2026 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 3,843 | $85K | 12/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 7,415 | $0 | 12/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 76 | $0 | 11/17/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 40 | $744 | 11/17/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 7,415 | $0 | 9/15/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 3,866 | $47K | 9/15/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 40 | $433 | 8/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 76 | $0 | 8/15/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 3,846 | $80K | 6/16/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 7,414 | $0 | 6/16/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 304 | $0 | 5/15/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 113 | $3K | 5/15/2025 | View on chart |
| TNDM | ▲ Buy | Grant | 870 | $17K | 5/15/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 7,415 | $0 | 3/17/2025 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 2,739 | $53K | 3/17/2025 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 29,658 | $0 | 12/16/2024 | View on chart |
| TNDM | ▼ Sell | Tax Withholding | 10,732 | $351K | 12/16/2024 | View on chart |
| TNDM | ▲ Buy | Open Market | 532 | $12K | 11/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.